Risk of secondary malignancies in patients with ovarian cancer: a systematic review and meta-analysis

Objective: This study was performed to systematically assess the risk of secondary malignancies in patients with ovarian cancer. Methods: A systematic search was conducted in PubMed, Web of Science, and Scopus databases up to September 2019. In this study, the overall standardized incidence ratio (SIR) was calculated applying fixed/random-effects models. Sixteen cohort studies, including 122715 ovarian cancer patients with 4458 secondary malignancies were included. Results: Combined SIRs showed an increased risk of secondary malignancies prevalence (SIR = 1.81, 95% CI 1.58--2.03). The most common malignancies were cervical cancer 11.57 (6.94-- 16.21), endometrium 6.31 (4.18--8.44), leukemia 3.33 (2.23--4.43), connective tissue 2.61 (1.56--3.66), bladder 2.13 (1.77--2.50), renal 1.43 (1.11--1.74), intestine 2.36 (1.11--3.61), colorectal 1.73 (1.44--2.02), pancreatic 1.42 (1.13--1.71), breast 1.34 (1.5--1.18), and thyroid 1.59 (1.13-- 2.04) cancers. Conclusion: Somemalignancieswerefoundtobehighly prevalent in patients with ovarian cancer compared to the general population, including endometrial cancer, leukemia, connective tissue malignancy, and bladder cancer. Therefore, efforts for early detection, which could lead to improved survival should be taken in these patients.

Ovarian cancer; Secondary malignancy; Secondary cancer; SIR; Meta-analysis

[1] IARC. Globocan 2018. In: Globocan. 2018.

[2] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136: E359–E386.

[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69: 7–34.

[4] Kim JY, Jang WY, Heo MH, Lee KK, Do YR, Park KU, et al. Metachronous double primary cancer after diagnosis of gastric cancer. Cancer Research and Treatment. 2012; 44: 173–178.

[5] Yoshino K, Asanuma F, Hanatani Y, Otani Y, Kumai K, Ishibiki K. Multiple primary cancers in the stomach and another organ: frequency and the effects on prognosis. Japanese Journal of Clinical Oncology. 1985; 15: 183–190.

[6] Kim C, Chon HJ, Kang B, Kim K, Jeung H-C, Chung HC, et al. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer. 2013; 13: 394.

[7] Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecologic Oncology. 2016; 143: 270–275.

[8] Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Annals of Internal Medicine. 1994; 121: 124–132.

[9] Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. Journal of the American Medical Association. 2011; 305: 2295–2303.

[10] Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet. 2016; 387: 945–956.

[11] Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstetrics and Gynecology. 1992; 80: 700–707.

[12] Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. Journal of the American Medical Association. 2019; 322: 652–665.

[13] Moyer VA. Screening for ovarian cancer: US preventive services Task Force reaffirmation recommendation statement. Annals of Internal Medicine. 2012; 157: 900–904.

[14] Nguyen J, Vicus D, Bernardini M, Hogen L. 314 patients with ovarian clear cell carcinoma are at high risk of secondary malignancy. In: 314 patients with ovarian clear cell carcinoma are at high risk of secondary malignancy. BMJ Specialist Journals. 2019.

[15] Reimer RR, Hoover R, Fraumeni Jr JF, Young RC. Second primary neoplasms following ovarian cancer. Journal of the National Cancer Institute. 1978; 61: 1195–1197.

[16] Storm HH, Ewertz M. Second cancer following cancer of the female genital system in Denmark, 1943–80. National Cancer Institute monograph. 1985; 68: 331–340.

[17] Kaldor J, Day N, Band P, Choi N, Clarke E, Coleman M, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin’s disease: an international collaborative study among cancer registries. International journal of cancer. 1987; 39: 571– 585.

[18] Levi F, Randimbison L, Te V, Rolland-Portal I, Franceschi S, La Vecchia C. Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974–89. British Journal of Cancer. 1993; 67: 391.

[19] Travis LB, Curtis RE, Boice JD, Platz CE, Hankey BF, Fraumeni JF. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Research. 1996; 56: 1564–1570.

[20] Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstetrics & Gynecology. 2012; 120: 612–618.

[21] Brookfield KF, Cheung MC, Koniaris LG, Sola JE, Fischer AC. A population-based analysis of 1037 malignant ovarian tumors in the pediatric population. Journal of Surgical Research. 2009; 156: 45–49.

[22] Zikry J, Korta DZ, Chapman LW, Linden KG. Melanoma arising in an ovarian cystic teratoma: a systematic review of presentation, treatment, and outcomes. Archives of Gynecology and Obstetrics. 2017; 296: 397–404.

[23] Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, et al. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. Journal of Medical Genetics. 1999; 36: 369–373.

[24] King M-C, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302: 643–646.

[25] Gershoni-Baruch R, Dagan E, Fried G, Bar-Sade RB, SverdlovShiri R, Zelicksson G, et al. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. European Journal of Cancer. 2000; 36: 983–986.

[26] Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute. 2002; 94: 1358– 1365.

[27] Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. The American Journal of Human Genetics. 2000; 66: 1259–1272.

[28] Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecologic Oncology. 2013; 130: 127–131.

[29] Consortium BCL. Cancer risks in BRCA2 mutation carriers. Journal of the National Cancer Institute. 1999; 91: 1310–1316.

[30] Iqbal J, Ragone A, Lubinski J, Lynch H, Moller P, Ghadirian P, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. British journal of cancer. 2012; 107: 2005–2009.

[31] Moran A, O’hara C, Khan S, Shack L, Woodward E, Maher E, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer. 2012; 11: 235– 242.

[32] Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, et al. BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute. 2018; 110: 1178–1189.

[33] Jarvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, Peltomaki P, Aaltonen LA, Mecklin J-P. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. Journal of Clinical Oncology. 2009; 27: 4793–4797.

[34] Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics. 2009; 75: 141–149.

[35] Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. Journal of the American Medical Association. 2011; 305: 2304–2310.

[36] Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, et al. The risk of extra‐colonic, extra‐endometrial cancer in the Lynch syndrome. International Journal of Cancer. 2008; 123: 444– 449.

[37] Coburn S, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. International Journal of Cancer. 2017; 140: 2451–2460.

[38] Denlinger CS, Weinberg DS. Sporadic breast, ovarian, or uterine cancers as risk factors for colorectal cancer. Current Colorectal Cancer Reports. 2009; 5: 24–29.

[39] Vega-Stromberg T. Chemotherapy-induced secondary malignancies. Journal of Infusion Nursing. 2003; 26: 353–361.

[40] Braunstein S, Nakamura JL. Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Frontiers in Oncology. 2013; 3: 73.

[41] Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wik- lund T, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. New England Journal of Medicine. 1999; 340: 351–357.

[42] Travis LB, Curtis RE, Boice Jr JD, Platz CE, Hankey BF, Fraumeni Jr JF. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Research. 1996; 56: 1564–1570.

[43] Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine. 2006; 354: 34–43.

[44] Boyd LR, Muggia FM. Carboplatin/paclitaxel induction in ovarian cancer: the finer points. 2018.

[45] Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart MJ, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecologic Oncology. 2017; 146: 484–490.

[46] Berg T, Nøttrup TJ, Roed H. Gemcitabine for recurrent ovarian cancer-a systematic review and meta-analysis. Gynecologic Oncology. 2019; 155: 530–537.

[47] Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute. 2010; 102: 193–201.

[48] Dash R, Doud L. Correlation of pap smear abnormalities in endometrial adenocarcinomas. Acta Cytol. 2001; 45: 835.

[49] Kimura T, Kamiura S, Yamamoto T, Seino‐Noda H, Ohira H, Saji F. Abnormal uterine bleeding and prognosis of endometrial cancer. International Journal of Gynecology & Obstetrics. 2004; 85: 145–150.

[50] Seebacher V, Schmid M, Polterauer S, Hefler-Frischmuth K, Leipold H, Concin N, et al. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer. 2009; 9: 460.

[51] Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. The Journal of Urology. 1992; 148: 788–790.

[52] Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, et al. Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. European urology. 2020; 77: 583–598.

[53] Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a com- prehensive literature review and meta-analyses. Urology. 2003; 61: 109–118.

[54] Bangma CH, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. European Urology. 2013; 64: 41–47.

[55] Qu X, Huang X, Wu L, Huang G, Ping X, Yan W. Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: a meta-analysis. European Journal of Radiology. 2011; 80: 188–197.

[56] Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica. 2011; 96: 1161–1169.

[57] Kalager M, Bretthauer M. Improving cancer screening programs. Science. 2020; 367: 143–144.

[58] Prior P, Pope DJ. Subsequent primary cancers in relation to treatment of ovarian cancer. British Journal of Cancer. 1989; 59: 453– 459.

[59] Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary malignancies following gynecological tumours in Saarland, Germany, 1968–1987. Journal of Cancer Research and Clinical Oncology. 1993; 119: 179–183.

[60] Bergfeldt K, Einhorn S, Rosendahl I, Hall P. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study. Acta Oncologica. 1995; 34: 771– 777.

[61] McCredie MRE, Macfarlane GJ, Coates MS, Osborn RA. Risk of second malignant neoplasms following female genital tract cancers in New South Wales (Australia), 1972–91. International Journal of Gynecological Cancer. 1996; 6: 362–368.

[62] Frenkel Y, Menczer J, Gaynor JJ, Blumstein T, Modan B. Second primary cancers in a cohort of Israeli women with primary gynecologic malignancies. Gynecologic Oncology. 1996; 61: 61–67.

[63] Weinberg DS, Newschaffer CJ, Topham A. Risk for colorectal cancer after gynecologic cancer. Annals of Internal Medicine. 1999; 131: 189–193.

[64] Hemminki K, Aaltonen L, Li X. Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. Cancer. 2003; 97: 2432–2439.

[65] van Niekerk CC, Vooijs GP, Bulten J, van Dijck J, Verbeek ALM. Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor. Modern Pathology. 2007; 20: 384–388.